Repligen

Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus, with revenue of $204.1M slightly beating the $201.4M estimate, while GAAP EPS of $0.09 significantly missed the $0.28 consensus due to a $13.7M loss on the Polymem divestiture and an elevated 64.6% effective tax rate. Gross margin reached 53.9%, outperforming the 53.3% mean expectation, driven by favorable product mix. The announcement of a $1.5B BioLife Solutions acquisition marks a major strategic shift toward cell therapy, though it introduces near-term integration and dilution risks.